About the Northline Ibogaine Brief

Our mission

Northline Ibogaine Brief exists to give Americans a clear, current, non-sensational picture of where ibogaine access actually stands. The topic is crowded with marketing and anecdote; our job is to separate what the law says, what the evidence shows, and what a responsible, lawful route looks like — without hype and without fear-mongering.

How we report

We work from primary and authoritative sources: federal scheduling and regulatory materials, peer-reviewed and clinical literature, official policy announcements, and the published protocols of treatment programs. Where facts are uncertain or contested, we say so. Cardiac safety, informed consent and continuous monitoring are treated as non-negotiable throughout our coverage.

What we are not

We are not a clinic, a treatment provider, a referral broker, or a medical authority, and nothing here is medical, legal or financial advice. We describe the landscape; decisions about treatment belong with qualified clinicians and, where relevant, legal counsel.

Independence

Our editorial judgments are our own. When we point readers to outside resources, it is to illustrate how programs describe their own standards — not as an endorsement. Read our editorial scope or send a correction via Contact.

Start with the guides

New here? Begin with the legal status of ibogaine, then safety and cardiac risk, cost, and what to expect.